BridgeBio Oncology Therapeutics (BBOT) vs Fulcrum Therapeutics (FULC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Fulcrum Therapeutics (FULC) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 60.3% versus a loss of 71.8%. Fulcrum Therapeutics is the larger company by market cap ($280.0 million vs $275.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | FULC |
|---|---|---|
| Share price | $3.44 | $3.67 |
| Market cap | $275.80M | $280.01M |
| 1-day change | -1.71% | -0.54% |
| YTD return | -72.52% | -67.55% |
| 1-year return | -71.83% | -60.28% |
| 5-year return | — | -85.88% |
| EPS (TTM) | $-0.07 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $15.74 |
| 52-week low | $3.36 | $2.83 |
| Distance from 52-week high | -76.87% | -76.68% |
| Average volume | 471.17K | 1.56M |
| Shares outstanding | 80.17M | 76.30M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FULC has outperformed BBOT by 11.5 percentage points over the past year.
BBOT vs FULC FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) is larger, with a market capitalization of $280.01M compared with $275.80M for BridgeBio Oncology Therapeutics (BBOT).
Which stock has performed better over the past year, BBOT or FULC?
FULC returned -60.28% over the past 12 months, compared with -71.83% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Fulcrum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.